{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:02:17Z","timestamp":1790600537597,"version":"4.1.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","award":["ECTZ7119091"],"award-info":[{"award-number":["ECTZ7119091"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les H\u00e9patites Virales","doi-asserted-by":"publisher","award":["APP 2020-1"],"award-info":[{"award-number":["APP 2020-1"]}],"id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["337146"],"award-info":[{"award-number":["337146"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004963","name":"Seventh Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100027503","name":"Center for Truth in Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100027503","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.celrep.2025.116705","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T22:32:09Z","timestamp":1765837929000},"page":"116705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["In vivo efficacy of combined human broadly neutralizing antibodies against hepatitis B virus"],"prefix":"10.1016","volume":"44","author":[{"given":"Maxime","family":"Beretta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel","family":"Mechaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Planchais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Haouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia","family":"Caillet-Saguy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Szerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yada","family":"Aronthippaitoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-No\u00eblle","family":"Ungeheuer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Gaudy-Graffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camille","family":"Sureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryline","family":"Bourgine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Mouquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2025.116705_bib1","series-title":"Global Hepatitis Report 2024: Action for Access in Low-And Middle-Income Countries","author":"Organization","year":"2024"},{"key":"10.1016\/j.celrep.2025.116705_bib2","series-title":"Hepatitis B Virus in Human Diseases","first-page":"217","article-title":"Natural History of Hepatitis B Virus Infection","author":"Chu","year":"2016"},{"key":"10.1016\/j.celrep.2025.116705_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41577-021-00549-4","article-title":"Immunobiology and pathogenesis of hepatitis B virus infection","volume":"22","author":"Iannacone","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.celrep.2025.116705_bib4","series-title":"Hepatitis B Virus in Human Diseases. Molecular and Translational Medicine","first-page":"1","article-title":"Hepatitis B Virus Virology and Replication","author":"Hu","year":"2016"},{"key":"10.1016\/j.celrep.2025.116705_bib5","series-title":"Hepatitis B Virus in Human Diseases","first-page":"63","article-title":"Hepatitis B Virus Genotypes","author":"Kato","year":"2016"},{"key":"10.1016\/j.celrep.2025.116705_bib6","series-title":"Hepatitis B Virus in Human Diseases","first-page":"1","article-title":"Hepatitis B Virus Virology and Replication","author":"Hu","year":"2016"},{"key":"10.1016\/j.celrep.2025.116705_bib7","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.jhep.2016.01.026","article-title":"Adaptive immunity in HBV infection","volume":"64","author":"Bertoletti","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.celrep.2025.116705_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.antiviral.2010.04.006","article-title":"Analysis of the epitope and neutralizing capacity of human monoclonal antibodies induced by hepatitis B vaccine","volume":"87","author":"Tajiri","year":"2010","journal-title":"Antiviral Res."},{"key":"10.1016\/j.celrep.2025.116705_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.coviro.2018.04.002","article-title":"Viral envelope-specific antibodies in chronic hepatitis B virus infection","volume":"30","author":"Corti","year":"2018","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.celrep.2025.116705_bib10","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"eLife"},{"key":"10.1016\/j.celrep.2025.116705_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2022.101205","article-title":"Advances in human monoclonal antibody therapy for HBV infection","volume":"53","author":"Beretta","year":"2022","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.celrep.2025.116705_bib12","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B Virus Infection \u2014 Natural History and Clinical Consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.celrep.2025.116705_bib13","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3390\/vaccines5030024","article-title":"Immune evasion strategies during chronic hepatitis B and C virus infection","volume":"5","author":"Ortega-Prieto","year":"2017","journal-title":"Vaccines"},{"key":"10.1016\/j.celrep.2025.116705_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104816","article-title":"Mechanisms of HBV immune evasion","volume":"179","author":"Kuipery","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.celrep.2025.116705_bib15","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/s41575-019-0196-9","article-title":"Restoring, releasing or replacing adaptive immunity in chronic hepatitis B","volume":"16","author":"Maini","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.celrep.2025.116705_bib16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1053\/j.gastro.2018.10.032","article-title":"Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection","volume":"156","author":"Gehring","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.celrep.2025.116705_bib17","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200840","article-title":"Potent human broadly neutralizing antibodies to hepatitis B virus from natural controllers","volume":"217","author":"Hehle","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.celrep.2025.116705_bib18","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jim.2007.09.017","article-title":"Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning","volume":"329","author":"Tiller","year":"2008","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.celrep.2025.116705_bib19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/vim.2006.19.277","article-title":"Study of IgG subclass profiles of anti-HBs in populations with different HBV infection status","volume":"19","author":"Tsai","year":"2006","journal-title":"Viral Immunol."},{"key":"10.1016\/j.celrep.2025.116705_bib20","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1002\/eji.201646446","article-title":"Scarcity of autoreactive human blood IgA+ memory B cells","volume":"46","author":"Prigent","year":"2016","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.celrep.2025.116705_bib21","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.chom.2020.05.010","article-title":"A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations","volume":"28","author":"Wang","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.celrep.2025.116705_bib22","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrgastro.2009.107","article-title":"Hepatitis B virus variants","volume":"6","author":"Chotiyaputta","year":"2009","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.celrep.2025.116705_bib23","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2012.05.009","article-title":"Influence of mutations in hepatitis B virus surface protein on viral antigenicity and phenotype in occult HBV strains from blood donors","volume":"57","author":"Huang","year":"2012","journal-title":"J. Hepatol."},{"key":"10.1016\/j.celrep.2025.116705_bib24","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.4254\/wjh.v7.i27.2729","article-title":"Clinical significance of hepatitis B surface antigen mutants","volume":"7","author":"Coppola","year":"2015","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.celrep.2025.116705_bib25","doi-asserted-by":"crossref","first-page":"7653","DOI":"10.3748\/wjg.v20.i24.7653","article-title":"Clinical implications of hepatitis B virus mutations: Recent advances","volume":"20","author":"Lazarevic","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.celrep.2025.116705_bib26","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0161-5890(99)00074-7","article-title":"Characterization of neutralizing anti-pre-S1 and anti-pre-S2 (HBV) monoclonal antibodies and their fragments","volume":"36","author":"K\u00fcttner","year":"1999","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.celrep.2025.116705_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jhep.2010.10.019","article-title":"N-terminal myristoylation-dependent masking of neutralizing epitopes in the preS1 attachment site of hepatitis B virus","volume":"55","author":"Bremer","year":"2011","journal-title":"J. Hepatol."},{"key":"10.1016\/j.celrep.2025.116705_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0212559","article-title":"HBV preS deletion mapping using deep sequencing demonstrates a unique association with viral markers","volume":"14","author":"Suzuki","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.celrep.2025.116705_bib29","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/978-1-60761-688-7_25","article-title":"The use of hepatocytes to investigate HDV infection: the HDV\/HepaRG model","volume":"640","author":"Sureau","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.celrep.2025.116705_bib30","doi-asserted-by":"crossref","first-page":"5554","DOI":"10.1128\/JVI.03134-12","article-title":"Adeno-Associated Virus-Mediated Gene Transfer Leads to Persistent Hepatitis B Virus Replication in Mice Expressing HLA-A2 and HLA-DR1 Molecules","volume":"87","author":"Dion","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2025.116705_bib31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.antiviral.2006.06.009","article-title":"Solution conformation of an immunodominant epitope in the hepatitis B virus preS2 surface antigen","volume":"72","author":"Chi","year":"2006","journal-title":"Antiviral Res."},{"key":"10.1016\/j.celrep.2025.116705_bib32","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.jmb.2007.05.022","article-title":"Inference of Macromolecular Assemblies from Crystalline State","volume":"372","author":"Krissinel","year":"2007","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.celrep.2025.116705_bib33","doi-asserted-by":"crossref","first-page":"946","DOI":"10.4161\/mabs.26390","article-title":"A bispecific antibody against two different epitopes on hepatitis B surface antigen has potent hepatitis B virus neutralizing activity","volume":"5","author":"Tan","year":"2013","journal-title":"mAbs"},{"key":"10.1016\/j.celrep.2025.116705_bib34","doi-asserted-by":"crossref","first-page":"9230","DOI":"10.1073\/pnas.0701279104","article-title":"Broadly neutralizing anti-hepatitis B virus antibody reveals a complementarity determining region H3 lid-opening mechanism","volume":"104","author":"Chi","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2025.116705_bib35","doi-asserted-by":"crossref","first-page":"9214","DOI":"10.1073\/pnas.0603316103","article-title":"Neutralization epitope responsible for the hepatitis B virus subtype-specific protection in chimpanzees","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2025.116705_bib36","doi-asserted-by":"crossref","first-page":"e26738","DOI":"10.7554\/eLife.26738","article-title":"A potent human neutralizing antibody Fc-dependently reduces established HBV infections","volume":"6","author":"Li","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.celrep.2025.116705_bib37","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/jvh.13880","article-title":"Development of monoclonal antibodies to target the large surface protein of hepatitis B virus and their use in therapeutic and diagnostic applications","volume":"30","author":"Paul","year":"2023","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.celrep.2025.116705_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01680-20","article-title":"Identification of Two Critical Neutralizing Epitopes in the Receptor Binding Domain of Hepatitis B Virus preS1","volume":"95","author":"Yato","year":"2021","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2025.116705_bib39","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.26738","article-title":"A potent human neutralizing antibody Fc-dependently reduces established HBV infections","volume":"6","author":"Li","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.celrep.2025.116705_bib40","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jmv.1890200204","article-title":"Monoclonal Antibody Recognizing Pre-S(2) Epitope of Hepatitis B Virus: Characterization of Pre-S(2) Epitope and Anti-Pre-S(2) Antibody","volume":"20","author":"Budkowska","year":"1986","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.celrep.2025.116705_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.virusres.2022.199014","article-title":"Identification of neutralizing epitopes in the preS2 domain of the hepatitis B virus","volume":"323","author":"Yato","year":"2023","journal-title":"Virus Res."},{"key":"10.1016\/j.celrep.2025.116705_bib42","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/(SICI)1096-9071(199706)52:2<226::AID-JMV18>3.0.CO;2-I","article-title":"In vitro neutralization of hepatitis b virus by monoclonal antibodies against the viral surface antigen","volume":"52","author":"Ryu","year":"1997","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.celrep.2025.116705_bib43","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/gutjnl-2014-308964","article-title":"Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen","volume":"65","author":"Zhang","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.celrep.2025.116705_bib44","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0378-1119(92)90139-G","article-title":"Cloning and characterization of cDNAs coding for heavy and light chains of a monoclonal antibody specific for pre-S2 antigen of hepatitis B virus","volume":"121","author":"Hong","year":"1992","journal-title":"Gene"},{"key":"10.1016\/j.celrep.2025.116705_bib45","first-page":"369","article-title":"Mapping of immunodominant B-cell epitopes and the human serum albumin-binding site in natural hepatitis B virus surface antigen of defined genosubtype","volume":"81","author":"Sobotta","year":"2000","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.celrep.2025.116705_bib46","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1089\/vim.2017.0200","article-title":"Interaction of S17 antibody with the functional binding region of the hepatitis B virus pre-S2 epitope","volume":"31","author":"Chang","year":"2018","journal-title":"Viral Immunol."},{"key":"10.1016\/j.celrep.2025.116705_bib47","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.4049\/jimmunol.137.8.2703","article-title":"Two distinct but overlapping antibody binding sites in the pre-S(2) region of HBsAg localized within 11 continuous residues","volume":"137","author":"Milich","year":"1986","journal-title":"J. Immunol."},{"key":"10.1016\/j.celrep.2025.116705_bib48","doi-asserted-by":"crossref","first-page":"9174","DOI":"10.1073\/pnas.83.23.9174","article-title":"A synthetic peptide vaccine involving the product of the pre-S(2) region of hepatitis B virus DNA: Protective efficacy in chimpanzees","volume":"83","author":"Itoh","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.celrep.2025.116705_bib49","article-title":"Both middle and large envelope proteins can mediate neutralization of hepatitis B virus infectivity by anti-preS2 antibodies: escape by naturally occurring preS2 deletions","volume":"98","author":"Jing","year":"2024","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2025.116705_bib50","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1128\/JVI.72.7.5573-5578.1998","article-title":"Role of the pre-S2 domain of the large envelope protein in hepatitis B virus assembly and infectivity","volume":"72","author":"Le Seyec","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2025.116705_bib51","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1128\/JVI.02528-09","article-title":"The Pre-S2 Domain of the Hepatitis B Virus Is Dispensable for Infectivity but Serves a Spacer Function for L-Protein-Connected Virus Assembly","volume":"84","author":"Ni","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2025.116705_bib52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jcv.2016.06.018","article-title":"PreS deletion profiles of hepatitis B virus (HBV) are associated with clinical presentations of chronic HBV infection","volume":"82","author":"Li","year":"2016","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.celrep.2025.116705_bib53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15252\/embr.201949351","article-title":"Anti- HIV -1 antibodies trigger non-lytic complement deposition on infected cells","volume":"21","author":"Dufloo","year":"2020","journal-title":"EMBO Rep."},{"key":"10.1016\/j.celrep.2025.116705_bib54","first-page":"219","article-title":"Potent Human Broadly SARS-CoV-2 \u2013 Neutralizing IgA and IgG Antibodies Effective against Omicron BA.1 and BA.2","volume":"1","author":"Planchais","year":"2022","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.celrep.2025.116705_bib55","first-page":"1","article-title":"Broadly neutralizing hemagglutinin stalk\u2013specific antibodies require Fc\u03b3R interactions for protection against influenza virus in vivo","volume":"23","author":"DiLillo","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.celrep.2025.116705_bib56","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jhep.2021.07.031","article-title":"Role of anti-HBs in functional cure of HBeAg+ chronic hepatitis B patients infected with HBV genotype A","volume":"76","author":"Xu","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.celrep.2025.116705_bib57","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1111\/liv.13716","article-title":"ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg-positive chronic hepatitis B","volume":"38","author":"Wong","year":"2018","journal-title":"Liver Int."},{"key":"10.1016\/j.celrep.2025.116705_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2024.105893","article-title":"Current and future use of antibody-based passive immunity to prevent or control HBV\/HDV infections","volume":"226","author":"Gehring","year":"2024","journal-title":"Antiviral Res."},{"key":"10.1016\/j.celrep.2025.116705_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(23)00606-2","article-title":"LBP-24 - Safety and efficacy of anti-pre-S1 domain monoclonal antibody (HH-003) treatment in patients with co-infection of chronic hepatitis B virus (HBV) and hepatitis D virus (HDV): a single center, open-label, phase 2 trial","volume":"78","author":"Wang","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.celrep.2025.116705_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236704","article-title":"A recombinant human immunoglobulin with coherent avidity to hepatitis B virus surface antigens of various viral genotypes and clinical mutants","volume":"15","author":"Jeong","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.celrep.2025.116705_bib61","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jhep.2023.07.003","article-title":"Potent broadly neutralizing antibody VIR-3434 controls hepatitis B and D virus infection and reduces HBsAg in humanized mice","volume":"79","author":"Lempp","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.celrep.2025.116705_bib62","unstructured":"ACTRN12623000111673 (2023). An optional multicenter, open-label Phase 2a multiple dose study in Chronic Hepatitis B (CHB) subjects to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778. https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ACTRN12623000111673."},{"key":"10.1016\/j.celrep.2025.116705_bib63","doi-asserted-by":"crossref","first-page":"S830","DOI":"10.1016\/S0168-8278(25)02134-8","volume":"82","author":"Yuen","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.celrep.2025.116705_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/S0168-8278(23)00488-9","article-title":"Safety and antiviral activity of short-duration combinations of the investigational small interfering ribonucleic acid VIR-2218 with the neutralizing, vaccinal monoclonal antibody VIR-3434: post-treatment follow-up from the Phase 2 MARCH trial","volume":"78","author":"Gane","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.celrep.2025.116705_bib65","doi-asserted-by":"crossref","first-page":"S1155","DOI":"10.1016\/S0168-8278(23)03292-0","article-title":"Single dose pharmacokinetics of VIR-3434, a novel neutralizing monoclonal antibody, in participants with chronic hepatitis B virus infection","volume":"78","author":"Gupta","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.celrep.2025.116705_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2022.101210","article-title":"The road to effective and accessible antibody therapies against Ebola virus","volume":"54","author":"Fausther-Bovendo","year":"2022","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.celrep.2025.116705_bib67","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/COH.0000000000000802","article-title":"Broadly neutralizing antibodies for HIV treatment and cure approaches","volume":"18","author":"Frattari","year":"2023","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.celrep.2025.116705_bib68","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1016\/j.cell.2021.05.005","article-title":"Tackling COVID-19 with neutralizing monoclonal antibodies","volume":"184","author":"Corti","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2025.116705_bib69","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1038\/d41586-022-00813-0","article-title":"Developing a cure for chronic hepatitis B requires a fresh approach","volume":"603","author":"Iannacone","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2025.116705_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2022.102207","article-title":"Immunological insights in the treatment of chronic hepatitis B","volume":"77","author":"Iannacone","year":"2022","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.celrep.2025.116705_bib71","doi-asserted-by":"crossref","DOI":"10.4254\/wjh.v17.i4.105797","article-title":"Drug development for chronic hepatitis B functional cure: Recent progress","volume":"17","author":"Liu","year":"2025","journal-title":"World J. Hepatol."},{"key":"10.1016\/j.celrep.2025.116705_bib72","article-title":"Engineered monoclonal antibody tobevibart enhances HBsAg capture by Fc receptor-positive cells and activates HBV-specific T cells","author":"Vincenzetti","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.celrep.2025.116705_bib73","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202305316","article-title":"A Dual-domain Engineered Antibody for Efficient HBV Suppression and Immune Responses Restoration","volume":"11","author":"Jiang","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.celrep.2025.116705_bib74","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/HEP.0000000000001179","article-title":"Enhanced hepatitis B virus\u2013specific immunity by combining neutralizing antibody therapy and DNA vaccination in a murine model of chronic hepatitis B virus infection","volume":"82","author":"Beretta","year":"2025","journal-title":"Hepatology"},{"key":"10.1016\/j.celrep.2025.116705_bib75","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1053\/j.gastro.2025.02.016","article-title":"The Impact of Hepatitis B Surface Antigen Reduction via Small Interfering RNA Treatment on Natural and Vaccine (BRII-179)-Induced Hepatitis B Virus-Specific Humoral and Cellular Immune Responses","volume":"169","author":"Ji","year":"2025","journal-title":"Gastroenterology"},{"key":"10.1016\/j.celrep.2025.116705_bib76","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/0264-410X(94)90155-4","article-title":"Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines","volume":"12","author":"Shouval","year":"1994","journal-title":"Vaccine"},{"key":"10.1016\/j.celrep.2025.116705_bib77","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S1473-3099(20)30780-5","article-title":"Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial","volume":"21","author":"Vesikari","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.celrep.2025.116705_bib78","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00430-014-0374-x","article-title":"Enhanced immune response to hepatitis B vaccination through immunization with a Pre-S1\/Pre-S2\/S Vaccine","volume":"204","author":"Shouval","year":"2015","journal-title":"Med Microbiol Immunol."},{"key":"10.1016\/j.celrep.2025.116705_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-32910-z","article-title":"Neutralization of hepatitis B virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen","volume":"13","author":"Washizaki","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.celrep.2025.116705_bib80","first-page":"1195","article-title":"Enhanced immunogenicity of the pre-s region of hepatitis B surface antigen","volume":"228","author":"Milich","year":"1985","journal-title":"Science (1979)"},{"key":"10.1016\/j.celrep.2025.116705_bib81","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.virusres.2015.10.024","article-title":"New broadly reactive neutralizing antibodies against hepatitis B virus surface antigen","volume":"211","author":"Kucinskaite-Kodze","year":"2016","journal-title":"Virus Res."},{"key":"10.1016\/j.celrep.2025.116705_bib82","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1084\/jem.20031550","article-title":"Surrogate Light Chain Expressing Human Peripheral B Cells Produce Self-reactive Antibodies","volume":"199","author":"Meffre","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.celrep.2025.116705_bib83","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.1086907","article-title":"Predominant Autoantibody Production by Early Human B Cell Precursors","volume":"301","author":"Wardemann","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.celrep.2025.116705_bib84","doi-asserted-by":"crossref","first-page":"9321","DOI":"10.1128\/JVI.00678-09","article-title":"A Function Essential to Viral Entry Underlies the Hepatitis B Virus \u201ca\u201d Determinant","volume":"83","author":"Salisse","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2025.116705_bib85","doi-asserted-by":"crossref","first-page":"9321","DOI":"10.1128\/JVI.00678-09","article-title":"A Function Essential to Viral Entry Underlies the Hepatitis B Virus \u201ca\u201d Determinant","volume":"83","author":"Salisse","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2025.116705_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110354","article-title":"Broad sarbecovirus neutralization by combined memory B cell antibodies to ancestral SARS-CoV-2","volume":"27","author":"Planchais","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.celrep.2025.116705_bib87","article-title":"Are International Units of Anti-HBs Antibodies Always Indicative of Hepatitis B Virus Neutralizing Activity?","volume":"11","author":"Aronthippaitoon","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.celrep.2025.116705_bib88","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1107\/S0021889807021206","article-title":"Phaser crystallographic software","volume":"40","author":"McCoy","year":"2007","journal-title":"J. Appl. Crystallogr."},{"key":"10.1016\/j.celrep.2025.116705_bib89","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1107\/S0907444912001308","article-title":"Towards automated crystallographic structure refinement with phenix.refine","volume":"68","author":"Afonine","year":"2012","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.celrep.2025.116705_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scisignal.2001906","article-title":"Inhibition of PP1 Phosphatase Activity by HBx: A Mechanism for the Activation of Hepatitis B Virus Transcription","volume":"5","author":"Cougot","year":"2012","journal-title":"Sci. Signal."},{"key":"10.1016\/j.celrep.2025.116705_bib91","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jim.2015.04.010","article-title":"Efficient generation of human IgA monoclonal antibodies","volume":"422","author":"Lorin","year":"2015","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.celrep.2025.116705_bib92","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1128\/JVI.79.3.1613-1622.2005","article-title":"Efficient Inhibition of Hepatitis B Virus Infection by Acylated Peptides Derived from the Large Viral Surface Protein","volume":"79","author":"Gripon","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.celrep.2025.116705_bib93","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.celrep.2019.03.032","article-title":"HIV-1 Envelope Recognition by Polyreactive and Cross-Reactive Intestinal B Cells","volume":"27","author":"Planchais","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2025.116705_bib94","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24244451","article-title":"High-throughput crystallization pipeline at the crystallography core facility of the institut pasteur","volume":"24","author":"Weber","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.celrep.2025.116705_bib95","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1107\/S0907444911007773","article-title":"Data processing and analysis with the autoPROC toolbox","volume":"67","author":"Vonrhein","year":"2011","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.celrep.2025.116705_bib96","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124725014779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124725014779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T12:51:50Z","timestamp":1790599910000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124725014779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":96,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2211124725014779"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2025.116705","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo efficacy of combined human broadly neutralizing antibodies against hepatitis B virus","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2025.116705","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116705"}}